The aim of this study was to evaluate the immunoreactivity of matrix metalloproteinases-2 (MMP-2), intercellular adhesion molecule-1 (ICAM-1), and nesfatin-1 in cataract lens epithelial cells (LECs) of patients with diabetes mellitus (DM) and to investigate the relationship of these markers with DM cataract and diabetic retinopathy (DR).
Materials and methods:
Ninety patients were included in the study. The patients were divided into three groups (n = 30): Group 1 (control; patients without DM or DR); Group 2 (patients with DM only), and Group 3 (patients with both DM and DR). Lens capsule samples were collected during intraoperative cataract surgery. Samples were immunohistochemically stained for MMP-2, ICAM-1, and nesfatin-1 and their immunoreactivity was evaluated. The number of immunoreactive cells was determined with a microscope at ×400 magnification.
Results:
Increased MMP-2 and ICAM-1 immunoreactivity was detected in the LECs of patients with DM, and especially in patients with DR (p < 0.001, p < 0.001, respectively). Nesfatin-1 immunoreactivity was significantly lower in LECs of diabetic patients (p < 0.001). The mean of MMP-2 immunoreactive cells were 7.47 ± 8.18, 22.80 ± 15.70, and 34.80 ± 20.85 in Groups 1, 2, and 3, respectively. The mean of ICAM-1 immunoreactive cells were 17.10 ± 9.83, 38.50 ± 23.55, and 56.93 ± 20.94 in Groups 1, 2, and 3, respectively.
Conclusion:
Nesfatin-1, MMP-2, and ICAM-1 and could potentially play important roles in the pathogenesis of cataracts in patients with DM.
KyselovaZStefekMBauerV.Pharmacological prevention of diabetic cataract. J Diabetes Complications2004; 18: 129–140.
2.
GuptaSKSelvanVKAgrawalSS, et al. Advances in pharmacological strategies for the prevention of cataract development. Indian J Ophthalmol2009; 57: 175–183.
3.
World Health Organization. Blindness: vision 2020. The global initiative for the elimination of avoidable blindness (Fact sheet 213). Geneva: WHO, 2000.
4.
World Health Organization. Visual impairment and blindness (Fact sheet 282). Geneva: WHO, 2012.
5.
HashimZZarinaS.Osmotic stress induced oxidative damage: possible mechanism of cataract formation in diabetes. J Diabetes Complications2012; 26: 275–279.
6.
MulhernMLMadsonCJDanfordA, et al. The unfolded protein response in lens epithelial cells from galactosemic rat lenses. Invest Ophthalmol Vis Sci2006; 47: 3951–3959.
7.
International Diabetes Federation (IDF). Diabetes atlas. 7th ed.Brussels: International Diabetes Federation, 2015. http://www.diabetesatlas.org (accessed 6 November 2015).
8.
KleinBEKleinRLeeKE.Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study. Am J Ophthalmol1998; 126: 782–790.
9.
RamanaKVFriedrichBBhatnagarA, et al. Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-alpha in human lens epithelial cells. FASEB J2003; 17: 315–317.
FolguerasARPendásAMSánchezLM, et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol2004; 48: 411–424.
12.
YılmazHHYazıhanNTuncaD.Cancer trends and ıncidence and mortality patterns in Turkey. Jpn J Clin Oncol2011; 41: 10–16.
13.
GiebelSJMenicucciGMcGuirePG, et al. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest2005; 85: 597–607.
14.
ShimizuHOh-ISHashimotoK, et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology2009; 150: 662–671.
15.
Oh-ISShimizuHSatohT, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature2006; 443: 709–712.
16.
SuYZhangJTangY, et al. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun2009; 391: 1039–1042.
17.
TangCHFuXJXuXL, et al. The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides2012; 36: 39–45.
18.
BarileGRChangSSParkLS, et al. Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Curr Eye Res1999; 19: 219–227.
19.
ZhangQAmesJMSmithRD, et al. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J Proteome Res2009; 8: 754–769.
20.
VorkaufMDunckerGNölleB, et al. Adhesion molecules in normal human conjunctiva. An immunohistological study using monoclonal antibodies. Graefes Arch Clin Exp Ophthalmol1993; 231: 323–330.
21.
PollreiszASchmidt-ErfurthU.Diabetic cataract-pathogenesis, epidemiology and treatment. J Ophthalmol2010; 2010: 608751.
22.
ObrosovaIGChungSSKadorPF.Diabetic cataracts: mechanisms and management. Diabetes Metab Res Rev2010; 26: 172–180.
23.
ZemaitieneR.Posterior capsule opacification: incidence and pathogenesis. Medicina2003; 39: 830–837.
24.
YeLLiQCaiX, et al. Expression of TGF-beta2 mRNA and PCNA, FN protein in lens epithelial cells in age-related nuclear and cortex cataract. J Huazhong Univ Sci Technol Med Sci2005; 25: 578–581.
25.
NishiONishiKAkaishiT, et al. Detection of cell adhesion molecules in lens epithelial cells of human cataracts. Invest Ophthalmol Vis Sci1997; 38: 579–585.
26.
FanHSuzukiTOgataM, et al. Expression of PCNA, ICAM-1, and vimentin in lens epithelial cells of cataract patients with and without type 2 diabetes. Tokai J Exp Clin Med2012: 20; 37: 51–56.
27.
CheungAKHFungMKLLoACY, et al. Aldose reductase deficiency prevents diabetes induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes2005; 54: 3119–3125.
28.
Abu-El-AsrarAMDralandsLMissotenL, et al. Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis2004; 45: 2760–2766.
29.
AdamisAP.Is diabetic retinopathy an inflammatory disease?Br J Ophthalmol2002; 86: 363–365.
30.
JoussenAMPoulakiVQinW, et al. Retinal vascular endothelial growth factor induces intercellular adhesion Molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol2002; 160: 501–509.
31.
MiyamotoKKhosrofSBursellSE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol2000; 156: 1733–1739.
32.
JonasJBJonasRANeumaierM, et al. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina2012; 32: 2150–2157.
33.
FunatsuHNomaHMimuraT, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology2009; 116: 73–79.
34.
El-ShabrawiYEckhardtMBergholdA, et al. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye (Lond)2000; 14(Pt 3A): 375–383.
35.
TamiyaSWormstoneIMMarcantonioJM, et al. Induction of matrix metalloproteinases 2 and 9 following stress to the lens. Exp Eye Res2000; 71: 591–597.
36.
SeomunYKimJLeeEH, et al. Overexpression of matrix metalloproteinase-2 mediates phenotypic transformation of lens epithelial cells. Biochem J2001; 358: 41–48.
37.
GiebelSJMenicucciGMcGuirePG, et al. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest2005; 85: 597–607.
38.
KłysikABNaduk-KikJHrabecZ, et al. Intraocular matrix metalloproteinase 2 and 9 in patients with diabetes mellitus with and without diabetic retinopathy. Arch Med Sci2010; 6: 375–381.
39.
DongJXuHXuH, et al. Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice. PLOS ONE2013; 8: e83397.
40.
LiuFYangQGaoN, et al. Decreased plasma nesfatin-1 level is related to the thyroid dysfunction in patients with type 2 diabetes mellitus. J Diabetes Res2014; 2014: 128014.
41.
DaiRDengGSunZ, et al. Relation of serum and vitreous nesfatin-1 concentrations with diabetic retinopathy. J Clin Lab Anal2017; 31: e22105.
